系统综述与Meta分析:溃疡性直肠炎的药物治疗
该系统综述与Meta分析检索了截至2022年11月23日的随机对照试验,纳入53项RCT(n=4096),评估溃疡性直肠炎药物治疗的疗效。结果显示,局部5-氨基水杨酸(5-ASA)在诱导和维持临床缓解方面均优于安慰剂,局部糖皮质激素和局部布地奈德在诱导缓解方面优于安慰剂,局部5-ASA联合局部糖皮质激素优于任一单药治疗,局部他克莫司和依曲莫德在诱导缓解方面优于安慰剂,依曲莫德在维持缓解方面亦优于安慰剂。
要点
- 局部5-ASA在诱导缓解(RR 2.72,95%CI 1.94-3.82)和维持缓解(RR 2.09,95%CI 1.26-3.46)方面均优于安慰剂。
- 局部糖皮质激素(RR 2.83,95%CI 1.62-4.92)和局部布地奈德(RR 2.34,95%CI 1.44-3.81)在诱导缓解方面优于安慰剂。
- 局部5-ASA联合局部糖皮质激素优于任一单药治疗;局部他克莫司和依曲莫德在诱导缓解方面优于安慰剂,依曲莫德在维持缓解方面亦优于安慰剂。
核心结论
- 局部5-ASA和糖皮质激素对活动性溃疡性直肠炎有效;局部5-ASA可能对维持缓解有效;他克莫司可能对诱导缓解有效;依曲莫德可能对诱导和维持缓解有效。
- 试验应纳入溃疡性直肠炎患者,以扩大这一代表性不足人群的证据基础。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、EMBASE和CENTRAL(2022年11月23日),纳入53项随机对照试验(n=4096),包括46项诱导研究(n=3731)和7项维持研究(n=365)。
- 研究对象为成人溃疡性直肠炎患者,评估药物治疗的疗效。
- 主要结局包括临床缓解的诱导和维持;计算合并风险比(RR)和95%置信区间(CI)。
主要发现
- 局部5-ASA在诱导缓解(RR 2.72,95%CI 1.94-3.82)和维持缓解(RR 2.09,95%CI 1.26-3.46)方面优于安慰剂。
- 局部糖皮质激素在诱导缓解方面优于安慰剂(RR 2.83,95%CI 1.62-4.92)。
- 局部布地奈德在诱导缓解方面优于安慰剂(RR 2.34,95%CI 1.44-3.81)。
- 局部5-ASA联合局部糖皮质激素优于任一单药治疗;局部他克莫司优于安慰剂。
- 依曲莫德在诱导缓解(RR 4.71,95%CI 1.2-18.49)和维持缓解(RR 2.08,95%CI 1.31-3.32)方面优于安慰剂。
关键数值与推荐
- 局部5-ASA vs 安慰剂:诱导缓解RR 2.72(95%CI 1.94-3.82),维持缓解RR 2.09(95%CI 1.26-3.46)。
- 局部糖皮质激素 vs 安慰剂:诱导缓解RR 2.83(95%CI 1.62-4.92)。
- 局部布地奈德 vs 安慰剂:诱导缓解RR 2.34(95%CI 1.44-3.81)。
- 依曲莫德 vs 安慰剂:诱导缓解RR 4.71(95%CI 1.2-18.49),维持缓解RR 2.08(95%CI 1.31-3.32)。
临床怎么用
- 局部5-ASA和糖皮质激素可用于活动性溃疡性直肠炎的治疗。
- 局部5-ASA可能用于维持缓解;他克莫司可能用于诱导缓解;依曲莫德可能用于诱导和维持缓解。
- 局部5-ASA联合局部糖皮质激素优于任一单药治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ulcerative proctitis (UP) is a common highly symptomatic form of ulcerative colitis that can be difficult to treat. AIM: To assess the efficacy of medical treatments for UP. METHODS: We searched MEDLINE, EMBASE, and CENTRAL on 23 November 2022 for randomised controlled trials (RCTs) of medical therapy for adults with UP. Primary outcomes included induction and maintenance of clinical remission. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated for each outcome. RESULTS: We included 53 RCTs (n = 4096) including 46 induction studies (n = 3731) and seven maintenance studies (n = 365). First-line therapies included topical 5-aminosalicylic acid (5-ASA), conventional corticosteroids, budesonide, and oral 5-ASA. Therapy for refractory UP included topical tacrolimus and small molecules. Topical 5-ASA was superior to placebo for induction (RR 2.72, 95% CI 1.94-3.82) and maintenance of remission (RR 2.09, 95% CI 1.26-3.46). Topical corticosteroids were superior to placebo for induction of remission (RR 2.83, 95% CI 1.62-4.92). Topical budesonide was superior to placebo for induction of remission (RR 2.34, 95% CI 1.44-3.81). Combination therapy with topical 5-ASA and topical corticosteroids was superior to topical monotherapy with either agent. Topical tacrolimus was superior to placebo. Etrasimod was superior to placebo for induction (RR 4.71, 95% CI 1.2-18.49) and maintenance of remission (RR 2.08, 95% CI 1.31-3.32). CONCLUSIONS: Topical 5-ASA and corticosteroids are effective for active UP. Topical 5-ASA may be effective for maintenance of remission. Tacrolimus may be effective for induction of remission. Etrasimod may be effective for induction and for maintenance of remission. Trials should include UP to expand the evidence base for this under-represented population.
引用
- Aruljothy A, Singh S, Narula N, et al. Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis. Aliment Pharmacol Ther. 2023. PMID: 37589498. doi:10.1111/apt.17666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。